ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (249 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmc.2005.02.056    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2005 Elsevier Ltd All rights reserved.

Indolizine 1-sulfonates as potent inhibitors of 15-lipoxygenase from soybeans

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Solomon Teklua, Lise-Lotte Gundersena, Corresponding Author Contact Information, E-mail The Corresponding Author, Tove Larsenb, Karl E. Malterudb and Frode Risea

aDepartment of Chemistry, University of Oslo, PO Box 1033, Blindern, N-0315 Oslo, Norway

bSchool of Pharmacy, University of Oslo, PO Box 1068, Blindern, N-0316 Oslo, Norway


Received 29 October 2004; 
accepted 25 February 2005. 
Available online 28 March 2005.

Abstract

A number of indolizine 1-sulfonates have been prepared by cyclization of cyclopropenones with pyridines followed by trapping of the intermediate 1-indolizinol with a sulfonyl halide, and examined as inhibitors of 15-lipoxygenase (15-LO). The compounds display IC50 values between 15 and 42 μM; all are more active than the well-known 15-LO inhibitor quercetin (IC50 51 μM). A wide variety of substituents are well tolerated. The enzyme inhibition was not affected by preincubation or the presence of a detergent and no significant particle formation was observed. Hence, inhibition from aggregates of indolizines, promiscuous inhibition, is highly unlikely.

Graphical abstract


Article Outline

1. Introduction
2. Results and discussion
3. Conclusions
4. Experimental
4.1. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile (3b)
4.2. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile (3c)
4.3. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile (3d)
4.4. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile (3e)
4.5. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-diethyl-7-indolizinecarbonitrile (3f)
4.6. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-dibutyl-7-indolizinecarbonitrile (3g)
4.7. 2,3-Diphenyl-1-indolizinol tosylate (3h)
4.8. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarboxaldehyde (3i)
4.9. 1-{[(4-Methylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinylethanone (3j)
4.10. 7-(1,1-Dimethylethyl)-2,3-diphenyl-1-indolizinol tosylate (3k)
4.11. 1-[(Methylsulfonyl)oxy]-2,3-diphenyl-7-indolizinecarbonitrile (3l)
4.12. 1-[(Butylsulfonyl)oxy]-2,3-diphenyl-7-indolizinecarbonitrile (3m)
4.13. 1-{[(2-Methyl)ethylsulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3n)
4.14. 1-[(N,N-Dimethylaminosulfonyl)oxy]-2,3-diphenyl-7-indolizinecarbonitrile (3p)
4.15. 1-[(Phenylsulfonyl)oxy]-2,3-diphenyl-7-indolizinecarbonitrile (3q)
4.16. 1-{[(2-Methylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3r)
4.17. 1-{[(2,4,6-Trimethylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3s)
4.18. 1-{{[4-(2-Methylethyl)phenyl]sulfonyl}oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3t)
4.19. 1-{[(4-Methoxyphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3u)
4.20. 1-{[(4-Methoxyphenyl)sulfonyl]oxy}-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile (3v)
4.21. 1-{[(2,4-Dimethoxyphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3w)
4.22. 1-{[(3,4-Dimethoxyphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3x)
4.23. 1-{[(2,5-Dimethoxyphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3y)
4.24. 1-{[(2-Thienyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3z)
4.25. 1-{[(3-Thienyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3aa)
4.26. 1-{[(4-Chlorophenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3bb)
4.27. 1-{[(4-Trifluoromethylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3cc)
4.28. 1-{[(4-Methylsulfonylphenyl)sulfonyl]oxy}-2,3-diphenyl-7-indolizinecarbonitrile (3dd)
4.29. 1-Bromo-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile (4b) and 1,6-dibromo-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile (5b)
4.30. 1-Bromo-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile (4b)
4.31. 1,6-Dibromo-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile (5b)
4.32. 1-Bromo-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile (4c) and 1,6-dibromo-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile (5c)
4.33. 1-Bromo-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile (4c)
4.34. 1,6-Dibromo-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile (5c)
4.35. 1-Bromo-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile (4d)
4.36. 1-[(4-Methylphenyl)sulfonyl]-2,3-diphenyl-7-indolizinecarbonitrile (6)
4.37. 2,3-Bis(4-fluorophenyl)-7-indolizinecarbonitrile (7b)
4.38. 2,3-Bis(4-chlorophenyl)-7-indolizinecarbonitrile (7c)
4.39. 2,3-Bis(4-methylphenyl)-7-indolizinecarbonitrile (7d)
4.40. 6,7-Diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate (9) and 6,7-diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate (10)
4.41. 6,7-Diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate (9)
4.42. 6,7-Diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate (10)
4.43. 6,7-Diphenylpyrrolo[1,2-a]pyrimidin-8-ol 3-diphenyl-2-propenoate (12)
4.44. Inhibition of 15-lipoxygenase
4.45. Inhibition of 15-lipoxygenase in preincubation experiment
4.46. Inhibition of 15-lipoxygenase in the presence of detergent
4.47. Dynamic light scattering (DLS)
Acknowledgements
References





Corresponding Author Contact InformationCorresponding author. Tel.: +47 22857019; fax: +47 22855507

 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.